Please do not leave this page until complete. This can take a few moments.
Sunovion announced Wednesday it has entered into an exclusive U.S. license agreement with Swiss drugmaker Novartis for three of its lung disease medicines.
Sunovion now has the exclusive rights to market Utibron Neohaler, Seebri Neohaler, and Arcapta Neohaler in the U.S., and plans to bring them to market in 2017. The licensing means the Marlborough company now has the broadest portfolio of chronic obstructive pulmonary disease treatments in the U.S. and can offer treatment options to people with all stages of the disease. Novartis will remain the manufacturer of the medicines, under the terms of the agreement.
Sunovion's existing portfolio includes Brovana, which can treat breathing problems; a long-acting beta agonist for more severe symptoms; and SUN-101/eFlow, a long-term maintenance breathing therapy for which Sunovion filed a new drug application to the U.S. Food and Drug Administration this past July. Financial details were not disclosed.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments